On this basis, we hypothesized that it could be valuable to explore whether a new model comprising the kallikrein markers included in PHI and the cancer-related markers of Proclarix may achieve higher values of sensitivity and specificity for the detection of both all cancers and csPCa than the tests alone. This evidence concerns the gene KLK4 and cancer.